News
CMPS
13.09
-4.80%
-0.66
How Investors May Respond To Compass Pathways Stock 52 Week Depression Trial Results
Simply Wall St · 1d ago
H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
TipRanks · 3d ago
Weekly Report: what happened at CMPS last week (0914-0918)?
Weekly Report · 3d ago
How Is COMPASS Pathways (CMPS) Shaping TRD Care Beyond Clinical Trial Results?
Simply Wall St · 09/17 02:22
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Barchart · 09/16 05:30
COMPASS Pathways (CMPS) Could Be 41% Undervalued On Phase 3 COMP360 Results
Simply Wall St · 09/15 13:21
Learn Why The Bull Case For COMPASS Pathways (CMPS) Could Change Following One Year Trial Results
Simply Wall St · 09/14 12:26
Weekly Report: what happened at CMPS last week (0907-0911)?
Weekly Report · 09/14 09:13
COMPASS Pathways (CMPS) Stock Looks Above Fair Value While Its 176% Return Stays Strong
Simply Wall St · 09/13 07:21
Strata Mental Health Solutions awarded training grant by Compass Pathways
TipRanks · 09/11 20:15
COMPASS Pathways (CMPS) Picks Five Groups For Provider Training Grants
Simply Wall St · 09/11 18:24
Psychedelic: Optimi to initiate Phase 2 trial of psilocybin-assisted therapy
TipRanks · 09/10 14:50
Analysts Are Bullish on These Healthcare Stocks: COMPASS Pathways (CMPS), Ocugen (OCGN)
TipRanks · 09/10 11:50
Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments
Benzinga · 09/10 10:41
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Barchart · 09/10 05:35
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Barchart · 09/10 05:30
COMPASS Pathways (CMPS) Reports 52 Week Phase 3 COMP360 Trial Results
Simply Wall St · 09/09 23:31
COMPASS Pathways: Strong Phase 3 TRD Data, Differentiated Positioning Support Unchanged $24 Price Target and Buy Rating
TipRanks · 09/09 19:55
Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression
Benzinga · 09/09 17:18
Midday Fly By: Analog acquires Alif, Independence Realty merges with Centerspace
TipRanks · 09/09 16:05
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.